Caffeine supplement, inflammation, and hepatic function in cirrhotic patients: A randomized, placebo- controlled, clinical trial
Aim: We investigated the possibility of caffeine supplementation for managing the inflammation, and hepatic function in cirrhotic patients. Methods: In this randomized, double-blind, placebo-controlled trial, fifty patients with cirrhosis were randomly assigned to receive either caffeine supplement...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024171691 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841526200665636864 |
|---|---|
| author | Seyed Ali Abbas-Hashemi Zahra Yari Behzad Hatami Amir Anushiravani Shadi Kolahdoozan Ali Zamanian Nadia Akbarzadeh Azita Hekmatdoost |
| author_facet | Seyed Ali Abbas-Hashemi Zahra Yari Behzad Hatami Amir Anushiravani Shadi Kolahdoozan Ali Zamanian Nadia Akbarzadeh Azita Hekmatdoost |
| author_sort | Seyed Ali Abbas-Hashemi |
| collection | DOAJ |
| description | Aim: We investigated the possibility of caffeine supplementation for managing the inflammation, and hepatic function in cirrhotic patients. Methods: In this randomized, double-blind, placebo-controlled trial, fifty patients with cirrhosis were randomly assigned to receive either caffeine supplement (400 mg), or placebo for eight weeks. Results: The results indicated a significant decrease in AST, platelets (P = 0.002), and PTT (P < 0.001), in the caffeine group compared to the placebo group. Also, caffeine supplementation resulted in a significant reduction in inflammatory biomarkers compared to placebo (p < 0.05). A significant improvement in liver indices including AST to platelet ratio index (APRI), (P < 0.001). Fibrosis 4 score (P < 0.001), and MELD score (P = 0.034)., was observed after 8 weeks caffeine supplementation. Conclusion: The results of the present study indicated that daily supplementation of 400 mg caffeine in cirrhotic patients can significantly improve liver fibrosis and reduce inflammatory factors.The trial was registered at the Iranian Registry of Clinical Trials (Registration ID: IRCT20100524004010N34). |
| format | Article |
| id | doaj-art-6495153b145748f0ab06b6f4b770de19 |
| institution | Kabale University |
| issn | 2405-8440 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj-art-6495153b145748f0ab06b6f4b770de192025-01-17T04:50:17ZengElsevierHeliyon2405-84402025-01-01111e41138Caffeine supplement, inflammation, and hepatic function in cirrhotic patients: A randomized, placebo- controlled, clinical trialSeyed Ali Abbas-Hashemi0Zahra Yari1Behzad Hatami2Amir Anushiravani3Shadi Kolahdoozan4Ali Zamanian5Nadia Akbarzadeh6Azita Hekmatdoost7Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Science, Tehran, IranDepartment of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Corresponding author.Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Science, Tehran, IranDigestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IranDigestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IranDepartment of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Science, Tehran, IranDepartment of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Science, Tehran, IranDepartment of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Science, Tehran, Iran; Corresponding author.Aim: We investigated the possibility of caffeine supplementation for managing the inflammation, and hepatic function in cirrhotic patients. Methods: In this randomized, double-blind, placebo-controlled trial, fifty patients with cirrhosis were randomly assigned to receive either caffeine supplement (400 mg), or placebo for eight weeks. Results: The results indicated a significant decrease in AST, platelets (P = 0.002), and PTT (P < 0.001), in the caffeine group compared to the placebo group. Also, caffeine supplementation resulted in a significant reduction in inflammatory biomarkers compared to placebo (p < 0.05). A significant improvement in liver indices including AST to platelet ratio index (APRI), (P < 0.001). Fibrosis 4 score (P < 0.001), and MELD score (P = 0.034)., was observed after 8 weeks caffeine supplementation. Conclusion: The results of the present study indicated that daily supplementation of 400 mg caffeine in cirrhotic patients can significantly improve liver fibrosis and reduce inflammatory factors.The trial was registered at the Iranian Registry of Clinical Trials (Registration ID: IRCT20100524004010N34).http://www.sciencedirect.com/science/article/pii/S2405844024171691CaffeineCirrhosisInflammationFibrosis |
| spellingShingle | Seyed Ali Abbas-Hashemi Zahra Yari Behzad Hatami Amir Anushiravani Shadi Kolahdoozan Ali Zamanian Nadia Akbarzadeh Azita Hekmatdoost Caffeine supplement, inflammation, and hepatic function in cirrhotic patients: A randomized, placebo- controlled, clinical trial Heliyon Caffeine Cirrhosis Inflammation Fibrosis |
| title | Caffeine supplement, inflammation, and hepatic function in cirrhotic patients: A randomized, placebo- controlled, clinical trial |
| title_full | Caffeine supplement, inflammation, and hepatic function in cirrhotic patients: A randomized, placebo- controlled, clinical trial |
| title_fullStr | Caffeine supplement, inflammation, and hepatic function in cirrhotic patients: A randomized, placebo- controlled, clinical trial |
| title_full_unstemmed | Caffeine supplement, inflammation, and hepatic function in cirrhotic patients: A randomized, placebo- controlled, clinical trial |
| title_short | Caffeine supplement, inflammation, and hepatic function in cirrhotic patients: A randomized, placebo- controlled, clinical trial |
| title_sort | caffeine supplement inflammation and hepatic function in cirrhotic patients a randomized placebo controlled clinical trial |
| topic | Caffeine Cirrhosis Inflammation Fibrosis |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024171691 |
| work_keys_str_mv | AT seyedaliabbashashemi caffeinesupplementinflammationandhepaticfunctionincirrhoticpatientsarandomizedplacebocontrolledclinicaltrial AT zahrayari caffeinesupplementinflammationandhepaticfunctionincirrhoticpatientsarandomizedplacebocontrolledclinicaltrial AT behzadhatami caffeinesupplementinflammationandhepaticfunctionincirrhoticpatientsarandomizedplacebocontrolledclinicaltrial AT amiranushiravani caffeinesupplementinflammationandhepaticfunctionincirrhoticpatientsarandomizedplacebocontrolledclinicaltrial AT shadikolahdoozan caffeinesupplementinflammationandhepaticfunctionincirrhoticpatientsarandomizedplacebocontrolledclinicaltrial AT alizamanian caffeinesupplementinflammationandhepaticfunctionincirrhoticpatientsarandomizedplacebocontrolledclinicaltrial AT nadiaakbarzadeh caffeinesupplementinflammationandhepaticfunctionincirrhoticpatientsarandomizedplacebocontrolledclinicaltrial AT azitahekmatdoost caffeinesupplementinflammationandhepaticfunctionincirrhoticpatientsarandomizedplacebocontrolledclinicaltrial |